Outcome of COVID‐19 in patients with autoimmune hepatitis: An international multicenter study
Hepatology — Efe C, Dhanasekaran R, Lammert C, et al. | June 21, 2021
An international multicenter study was conducted to evaluate outcome of COVID‐19 in patients with autoimmune hepatitis. Researchers conducted a retrospective study on patients with autoimmune hepatitis (AIH) and COVID-19 from 34 centers in Europe and the Americas. The examined factors correlated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. They compared outcomes of patients with AIH with a propensity score–matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. They further assessed frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19. The study enrolled 110 individuals with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. The results indicate that individuals with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. In patients with AIH, cirrhosis was the strongest predictor for severe COVID-19. During COVID-19, maintenance of immunosuppression was not correlated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.
Read the full article on Hepatology